Prevention and management of immune-related adverse events for biliary tract cancers
Immune checkpoint inhibitors (ICIs) combined with chemotherapy has become the first-line standard treatment for advanced biliary tract cancers (BTC). However, the application of ICIs comes with its risks of immune-related adverse events (irAEs). BTC patients often face greater challenges in the diag...
Saved in:
Main Author: | LIU Kun, GUO Wei |
---|---|
Format: | Article |
Language: | Chinese |
Published: |
Editorial Office of Journal of Surgery Concepts & Practice
2025-03-01
|
Series: | Waike lilun yu shijian |
Subjects: | |
Online Access: | https://www.qk.sjtu.edu.cn/jscp/fileup/1007-9610/PDF/1751876439817-1105793041.pdf |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Natural killer cell as a potential predictive biomarker for early immune checkpoint inhibitor-associated cardiovascular adverse events: a retrospective cohort study
by: Yujuan Wu, et al.
Published: (2025-07-01) -
Clinical outcomes of transarterial chemoembolization combined with durvalumab for advanced and metastatic biliary tract cancer
by: Yuefeng Hu, et al.
Published: (2025-12-01) -
Case Report: Immune checkpoint inhibitor-induced myositis without elevated creatine kinase
by: Klajdi Begaj, et al.
Published: (2025-06-01) -
Toxicity Associated with Immune Checkpoint Inhibitors: Analysis of Immune-Related Adverse Events with a Pembrolizumab Biosimilar (Pembroria)
by: M. Yu. Fedyanin, et al.
Published: (2023-06-01) -
Neurotoxicity in the Era of Immune Checkpoint Inhibitors: A Case-Based Approach
by: Özkan ALAN, et al.
Published: (2025-04-01)